AstraZeneca trial flop raises bigger question: Is its pipeline premium becoming more vulnerable? Shares down 6% worst day in 2 years. #AZN
#Biotech
$AZN (+0.12%)
4D·
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
2